NASDAQ:PPBT - Purple Biotech Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $25.00
  • Forecasted Upside: 354.55 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$5.50
▼ -0.02 (-0.36%)

This chart shows the closing price for PPBT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Purple Biotech Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PPBT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PPBT

Analyst Price Target is $25.00
▲ +354.55% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Purple Biotech in the last 3 months. The average price target is $25.00, with a high forecast of $25.00 and a low forecast of $25.00. The average price target represents a 354.55% upside from the last price of $5.50.

This chart shows the closing price for PPBT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Purple Biotech.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/9/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/9/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/7/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/5/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/3/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/4/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/3/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/2/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/31/2020HC WainwrightReiterated RatingBuy$25.00N/A
(Data available from 8/2/2016 forward)
Purple Biotech logo
Purple Biotech Ltd., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs in the United States. It operates through two segments, Oncology, and Pain and Hypertension. The company's marketed products include Consensi, a fixed-dose combination of celecoxib and amlodipine besylate for the simultaneous treatment of osteoarthritis pain and hypertension. Its oncology pipeline includes NT219, a small molecule that targets insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment of recurrent and/or metastatic solid tumors and squamous cell carcinoma of the head and neck cancer; and CM-24, a monoclonal antibody blocking CEACAM1 that is being developed as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer and pancreatic cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. Purple Biotech Ltd. was founded in 2010 and is headquartered in Rehovot, Israel.
Read More

Today's Range

Now: $5.50
Low: $5.38
High: $5.65

50 Day Range

MA: $5.04
Low: $4.42
High: $6.72

52 Week Range

Now: $5.50
Low: $3.60
High: $9.78

Volume

221,265 shs

Average Volume

632,382 shs

Market Capitalization

$142.68 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.09

Frequently Asked Questions

What sell-side analysts currently cover shares of Purple Biotech?

The following Wall Street sell-side analysts have issued reports on Purple Biotech in the last twelve months: HC Wainwright, and Zacks Investment Research.
View the latest analyst ratings for PPBT.

What is the current price target for Purple Biotech?

1 Wall Street analysts have set twelve-month price targets for Purple Biotech in the last year. Their average twelve-month price target is $25.00, suggesting a possible upside of 354.5%. HC Wainwright has the highest price target set, predicting PPBT will reach $25.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $25.00 for Purple Biotech in the next year.
View the latest price targets for PPBT.

What is the current consensus analyst rating for Purple Biotech?

Purple Biotech currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PPBT will outperform the market and that investors should add to their positions of Purple Biotech.
View the latest ratings for PPBT.

What other companies compete with Purple Biotech?

How do I contact Purple Biotech's investor relations team?

Purple Biotech's physical mailing address is ONE AZRIELI CENTER ROUND TOWER 132 MENACHEM BEGIN ROAD, TEL AVIV L3, 6701101. The company's listed phone number is 972 3 933 3121 and its investor relations email address is [email protected] The official website for Purple Biotech is www.kitovpharma.com.